Header Logo

Connection

Donald Jensen to Humans

Back to Details
This is a "connection" page, showing publications Donald Jensen has written about Humans.
Donald Jensen
Connection Strength
0.795
Humans
  1. The American Association for the Study of Liver Diseases: A history of the first 10 years and its presidents. Hepatology. 2022 09; 76(3):854-859.
    View in: PubMed
    Score: 0.043
  2. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther. 2019; 13:2565-2577.
    View in: PubMed
    Score: 0.036
  3. Generic medications for hepatitis C. Liver Int. 2016 07; 36(7):925-8.
    View in: PubMed
    Score: 0.029
  4. Faldaprevir, pegylated interferon, and ribavirin for treatment-na?ve HCV genotype-1: pooled analysis of two phase 3 trials. Ann Hepatol. 2016 May-Jun; 15(3):333-49.
    View in: PubMed
    Score: 0.029
  5. Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study. Liver Int. 2016 Apr; 36(4):505-14.
    View in: PubMed
    Score: 0.028
  6. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C. Liver Int. 2015 Jan; 35 Suppl 1:11-7.
    View in: PubMed
    Score: 0.026
  7. Human immunodeficiency virus and coinfection with hepatitis B and C. Infect Dis Clin North Am. 2014 Sep; 28(3):477-99.
    View in: PubMed
    Score: 0.025
  8. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology. 2014 Apr; 59(4):1246-9.
    View in: PubMed
    Score: 0.025
  9. Faster than a speeding bullet. Hepatology. 2014 Mar; 59(3):741-2.
    View in: PubMed
    Score: 0.024
  10. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment. J Clin Gastroenterol. 2013 Oct; 47(9):786-93.
    View in: PubMed
    Score: 0.024
  11. The FDA, bridging data, and hepatitis C. Hepatology. 2013 Mar; 57(3):875-7.
    View in: PubMed
    Score: 0.023
  12. Future therapies for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013 May; 10(5):268-76.
    View in: PubMed
    Score: 0.023
  13. The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus. Infect Dis Clin North Am. 2012 Dec; 26(4):879-91.
    View in: PubMed
    Score: 0.023
  14. Use of immune function test in monitoring immunosuppression in liver transplant recipients. Clin Transplant. 2012 Nov-Dec; 26(6):826-32.
    View in: PubMed
    Score: 0.022
  15. IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late? Liver Int. 2012 Feb; 32 Suppl 1:74-8.
    View in: PubMed
    Score: 0.021
  16. A new era of hepatitis C therapy begins. N Engl J Med. 2011 Mar 31; 364(13):1272-4.
    View in: PubMed
    Score: 0.020
  17. Treatment duration for genotypes 2 and 3: still confusing after all these years. J Clin Gastroenterol. 2010 Sep; 44(8):527-8.
    View in: PubMed
    Score: 0.019
  18. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010 Feb; 14(1):1-21, vii.
    View in: PubMed
    Score: 0.019
  19. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med. 2009 Apr 21; 150(8):528-40.
    View in: PubMed
    Score: 0.018
  20. Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cure. Liver Int. 2009 Apr; 29(4):481-2.
    View in: PubMed
    Score: 0.018
  21. Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: a case report. Dig Dis Sci. 2009 Jun; 54(6):1369-72.
    View in: PubMed
    Score: 0.017
  22. Hepatitis C: current and future therapies. Mt Sinai J Med. 2008 Aug; 75(4):405-14.
    View in: PubMed
    Score: 0.017
  23. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008 Aug; 103(8):1981-8.
    View in: PubMed
    Score: 0.017
  24. Current state of combined heart-liver transplantation in the United States. J Heart Lung Transplant. 2008 Jul; 27(7):753-9.
    View in: PubMed
    Score: 0.017
  25. Ribavirin in the treatment of chronic hepatitis C. J Gastroenterol Hepatol. 2008 Jun; 23(6):844-55.
    View in: PubMed
    Score: 0.017
  26. Vanishing bile duct syndrome. Clin Liver Dis. 2008 Feb; 12(1):203-17, x.
    View in: PubMed
    Score: 0.016
  27. Future directions in therapy for chronic hepatitis C. Antivir Ther. 2008; 13 Suppl 1:31-6.
    View in: PubMed
    Score: 0.016
  28. Retreatment of chronic hepatitis C in previous non-responders and relapsers. Expert Opin Pharmacother. 2007 Oct; 8(15):2491-503.
    View in: PubMed
    Score: 0.016
  29. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006 May; 43(5):954-60.
    View in: PubMed
    Score: 0.014
  30. Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin. Eur J Gastroenterol Hepatol. 2005 Sep; 17(9):899-904.
    View in: PubMed
    Score: 0.014
  31. The downstream financial effect of hepatology. Hepatology. 2005 May; 41(5):968-75.
    View in: PubMed
    Score: 0.013
  32. Serum enzymes associated with cholestasis. Clin Liver Dis. 2004 Feb; 8(1):41-54, vi.
    View in: PubMed
    Score: 0.012
  33. Neutralizing antibodies in hepatitis C virus infection: a review of immunological and clinical characteristics. Gastroenterology. 2003 Aug; 125(2):597-604.
    View in: PubMed
    Score: 0.012
  34. A pilot study of the combination of cyclosporin A and interferon alfacon-1 for the treatment of hepatitis C in previous nonresponder patients. J Clin Gastroenterol. 2003 Apr; 36(4):352-5.
    View in: PubMed
    Score: 0.012
  35. Characteristics of hepatitis C in renal transplant candidates. J Clin Gastroenterol. 2002 Aug; 35(2):191-5.
    View in: PubMed
    Score: 0.011
  36. Novel educational interventions in residency increase knowledge of chronic liver disease and career interest in hepatology. Hepatology. 2016 12; 64(6):2210-2218.
    View in: PubMed
    Score: 0.007
  37. Retinoid and carotenoid status in serum and liver among patients at high-risk for liver cancer. BMC Gastroenterol. 2016 Feb 29; 16:30.
    View in: PubMed
    Score: 0.007
  38. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. Liver Int. 2016 07; 36(7):954-62.
    View in: PubMed
    Score: 0.007
  39. A call to action: The need for hepatology-focused educational interventions in Internal Medicine Residency training. Hepatology. 2015 Aug; 62(2):655-6.
    View in: PubMed
    Score: 0.007
  40. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol. 2015 Feb; 62(2):294-302.
    View in: PubMed
    Score: 0.006
  41. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24; 370(17):1604-14.
    View in: PubMed
    Score: 0.006
  42. Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. Hepatology. 2012 Dec; 56(6):2398-403.
    View in: PubMed
    Score: 0.006
  43. Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. Expert Opin Drug Saf. 2012 Nov; 11(6):901-9.
    View in: PubMed
    Score: 0.006
  44. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann Hepatol. 2012 Jan-Feb; 11(1):15-31.
    View in: PubMed
    Score: 0.005
  45. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology. 2011 Sep 02; 54(3):789-800.
    View in: PubMed
    Score: 0.005
  46. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol. 2009 Apr; 50(4):797-804.
    View in: PubMed
    Score: 0.004
  47. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology. 2008 Oct; 48(4):1033-43.
    View in: PubMed
    Score: 0.004
  48. Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. J Clin Gastroenterol. 2004 Oct; 38(9):801-4.
    View in: PubMed
    Score: 0.003
  49. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol. 2003 Jul; 39(1):106-11.
    View in: PubMed
    Score: 0.003
  50. Adult living donor liver transplantation: perspectives from 100 liver transplant surgeons. Liver Transpl. 2003 Jun; 9(6):637-44.
    View in: PubMed
    Score: 0.003
  51. Induction of IL-1Ra in resistant and responsive hepatitis C patients following treatment with IFN-con1. J Interferon Cytokine Res. 2002 May; 22(5):549-54.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.